Director, Patient Cell Supply Chain at Lyell Immunopharma

Bothell, Washington, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Cell TherapyIndustries

Requirements

Experience managing day-to-day operations and execution of vein-to-vein supply chain for autologous cell therapies, including coordination from patient material collection to manufacturing and back to clinical sites
Expertise in operationalizing clinical programs, supporting cross-functional readiness, and ensuring patient cell therapies move safely, compliantly, and on schedule
Knowledge of execution across scheduling, logistics coordination, vendor management, clinical site training, and cold chain oversight
Ability to lead a team working with clinical sites, apheresis centers, manufacturing, and transportation partners to handle patient materials according to strict quality and regulatory standards
Capability to own systems, training programs, and vendor relationships to maintain supply continuity across clinical programs
Familiarity with GxP, temperature control requirements, COI/COC integrity, SOPs, vendor qualification, audit preparation, and issue resolution
Willingness to work in a hybrid role based in Bothell, Washington or South San Francisco, California

Responsibilities

Manage the coordination of patient scheduling, apheresis material collection, manufacturing slot assignment, and drug product return to clinical sites
Oversee end-to-end cold chain logistics operations, ensuring COI/COC integrity and compliance with GxP and temperature control requirements
Serve as the operational lead for daily supply chain activity—triaging delays, managing escalations, and ensuring patient shipments stay on track
Own day-to-day relationships with specialty couriers and packaging providers; ensure compliance with SOPs and quality expectations
Support vendor qualification, audit preparation, and issue resolution in collaboration with Quality and Compliance
Coordinate courier availability and performance to meet clinical trial and manufacturing timelines
Lead the oversight and execution of training for clinical and apheresis sites on the Apheresis Manual and Drug Product Administration Manual

Skills

Supply Chain Management

Vein-to-Vein Operations

Patient Material Coordination

Cell Therapy Logistics

Manufacturing Coordination

Clinical Supply Chain

Cell Collection

Biotech Supply Chain

GMP Compliance

Cold Chain Logistics

Lyell Immunopharma

Develops advanced cell therapies for cancer

About Lyell Immunopharma

Lyell Immunopharma develops advanced cell therapies aimed at treating solid tumors, which are cancerous tissue masses. The company focuses on enhancing T cells, a type of immune cell, to effectively target and eliminate cancer cells. Their approach includes genetic and epigenetic reprogramming of T cells to address challenges like T cell exhaustion and to ensure T cells can persist in the body. Unlike many competitors, Lyell is dedicated to creating curative treatments specifically for solid tumors, utilizing a diverse product pipeline that explores various treatment methods. The goal is to push the limits of current cancer therapies and provide effective solutions where traditional treatments have not succeeded.

San Francisco, CaliforniaHeadquarters

2018Year Founded

$479.6MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Commuter Benefits

Phone/Internet Stipend

Risks

Increased competition in T-cell therapies may impact Lyell's market share.

Delays in clinical data results could lead to investor uncertainty.

Integration challenges from ImmPACT Bio acquisition may divert focus from core operations.

Differentiation

Lyell focuses on T cell reprogramming to treat solid tumors effectively.

Their proprietary Gen-R and Epi-R platforms address T cell exhaustion and stemness.

Lyell's diverse product pipeline explores multiple treatment modalities for solid tumors.

Upsides

Acquisition of ImmPACT Bio enhances Lyell's CAR T-cell therapy capabilities.

Strategic partnership with MaxCyte boosts cell engineering and therapeutic development.

New leadership appointments strengthen Lyell's strategic direction and management.

Land your dream remote job 3x faster with AI

Try Jobo Free